DaVita
DVA
Bank of America
BAC
Chubb Ltd
CB
American Express
AXP
Moody's
MCO
US Stock MarketDetailed Quotes
STOK Stoke Therapeutics
- 8.680
- -0.240-2.69%
Close Jan 14 16:00 ET
459.75MMarket Cap-4.17P/E (TTM)
9.135High8.420Low916.88KVolume9.000Open8.920Pre Close8.04MTurnover2.50%Turnover RatioLossP/E (Static)52.97MShares17.58052wk High1.98P/B318.72MFloat Cap4.09052wk Low--Dividend TTM36.72MShs Float71.580Historical High--Div YieldTTM8.02%Amplitude3.350Historical Low8.767Avg Price1Lot Size
Stoke Therapeutics News
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics Analyst Ratings
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital
Stoke Therapeutics Initiated at Buy by Chardan Capital
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy Rating
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Stoke Therapeutics' Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy Rating
Stoke Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Trending US Stocks
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.